Department of Dermatology and Venereology, Reference Centre for Rare Skin Disorders, University Hospital of Toulouse, 24, chemin de Pouvourville, TSA 30030, 31059 Toulouse Cedex 9, France.
Department of Vascular Medicine, University Hospital of Toulouse, 1, avenue Jean-Poulhès, TSA 50032, 31059 Toulouse Cedex 9, France.
Ann Dermatol Venereol. 2021 Dec;148(4):233-237. doi: 10.1016/j.annder.2021.03.004. Epub 2021 Jul 1.
Oral propranolol (Pr) must be administered until the end of the proliferation phase of infantile haemangioma (IH). This phase may be difficult to assess, particularly where a deep component is involved. Doppler ultrasound scans (DUS), which identify vascular activity (VA), could assist the clinician in making the correct therapeutic decision (CTD).
All children with IH treated with Pr for at least 3 months and up to the age of 9 months, and who also underwent DUS, were enrolled in this retrospective, single-centre, observational study. The quality of DUS as a binary diagnostic test for IH proliferation was assessed, together with its value in deciding whether to discontinue Pr (at the end of the presumed proliferation phase) or resume this drug (in the case of suspected recurrence).
A total of 29 children were enrolled and 45 DUS were performed. Thirty-nine (87%) DUS were of high quality (80% sensitivity, 95% specificity) and made a major, moderate, or minimal contribution to the CTD in respectively 20%, 60% and 7% of cases.
DUS proved to be a high-value tool. They were essential in some cases of IH, mainly periocular and localised forms, and those involving deep components, in which the question of discontinuing Pr arose (age>1 year) and where clinical examination had not been sufficient to make the CTD. Furthermore, in the vast majority of cases, they provide a helpful examination and complement clinical findings in terms of patient follow-up and reaching a CTD.
DUS is an effective and complementary tool to clinical investigation.
口服用普萘洛尔(Pr)必须持续到婴儿血管瘤(IH)增殖期结束。这个阶段可能很难评估,尤其是涉及到深部成分的情况下。多普勒超声扫描(DUS)可以识别血管活动(VA),这可以帮助临床医生做出正确的治疗决策(CTD)。
所有接受 Pr 治疗至少 3 个月且年龄在 9 个月以下的 IH 患儿,以及接受 DUS 检查的患儿,均被纳入这项回顾性、单中心、观察性研究。评估 DUS 作为 IH 增殖的二进制诊断测试的质量,以及其在决定是否停止 Pr(在假定的增殖期结束时)或恢复该药物(在怀疑复发的情况下)的价值。
共纳入 29 例患儿,共进行了 45 次 DUS。39 次(87%)DUS 质量较高(80%的敏感性,95%的特异性),分别在 20%、60%和 7%的病例中对 CTD 的决策做出了重大、中度或轻度贡献。
DUS 被证明是一种高价值的工具。它们在一些 IH 病例中至关重要,主要是眼周和局限性的病例,以及涉及深部成分的病例,在这些病例中,需要考虑是否停止 Pr(年龄>1 岁),而临床检查不足以做出 CTD。此外,在绝大多数情况下,它们为患者的随访和做出 CTD 提供了有帮助的检查,并补充了临床发现。
DUS 是临床检查的有效补充工具。